Project Grant R41AG092194
Award Date 9/20/25
Completion Date 5/31/27
Dollars Obligated $255K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
- The National Institute on Aging (NIA) awarded a $442,357 Project Grant under the Aging Research program (CFDA 93.866) to the Research Foundation of the City University of New York (RFCUNY) on December 15, 2024. The grant aims to elucidate the molecular mechanisms that give rise to functionally neurodegenerative microglia, the brain's primary innate immune cells, which have been implicated as major determinants of Alzheimer's disease (AD) risk. The research will leverage novel mouse models and...
- This federal Project Grant award of $839,933 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research to investigate the role of N6-methyladenosine (m6A) RNA modifications in microglial dysfunction and Alzheimer's disease (AD) pathogenesis. The project aims to systematically map m6A modification landscapes in microglia isolated from human brain tissue and human induced pluripotent stem cell-derived microglial models. The researchers will also use CRISPR-based...
- This $810,596 Project Grant award from the National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), aims to develop a novel chimeric antigen receptor (CAR)-engineered macrophage (CAR-MI) therapy for Alzheimer's disease (AD). The goal is to create "off-the-shelf" human induced pluripotent stem cell (HIPSC)-derived CAR-MIs that can effectively target and clear misfolded proteins associated with AD pathology, while also modulating neuroinflammation....
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded Aivocode, Inc. a $1,244,775 project grant to develop single domain antibodies targeting Connective Tissue Growth Factor (CTGF) for improving vascular dysfunction in Alzheimer's disease. The award period runs from September 2025 to May 2027. The funding will support preclinical research to test these single domain antibodies in mouse models of Alzheimer's disease, with the goal of...
- The National Institute on Aging (NIA) awarded a $842,175 Project Grant under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on December 15, 2024, will fund research to explore the role of the NOX2 enzyme in mediating Alzheimer's disease (AD) pathologies, including network hyperactivity, glucose hypometabolism, and accumulation of amyloid-beta and tau proteins. The research aims to assess the therapeutic efficacy of a novel...
- This Project Grant award from the National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), will support the lead optimization of a therapeutic candidate for Alzheimer's disease (AD). The $349,605 award to Stress Therapeutics, Inc., a California-based biopharmaceutical company, aims to advance the development of a first-in-class treatment that can reduce hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis, a key pathogenic driver of AD...
- This Project Grant award titled "Epitranscriptomic Regulation of Microglia in Alzheimer's Disease" was provided by the National Institute on Aging (CFDA 93.866 - Aging Research) to Duke University. The $509,413 grant, awarded on September 15, 2025, will support research to understand the role of epitranscriptomic regulation, specifically the m6A modification, in controlling microglial function and its contribution to Alzheimer's disease pathogenesis. The project aims to elucidate how...
- This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $759,352 to investigate how shifts in microglial metabolism impact the progression of Alzheimer's disease (AD) and whether targeting metabolic flux can reduce AD-related pathology. The research aims to elucidate the role of lactate, a byproduct of glycolysis, in regulating immunometabolism and microglial activity in the context of AD. The 5-year award, starting on May 15,...